Board to Initiate CEO Search Process; Scott Hirsch Appointed as Interim CEO MALVERN, Pa. , Aug. 27, 2024 /CNW/ -- Endo, Inc.
(OTCQX: NDOI) ("Endo" or the "Company"), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies, today announced that the Board of Directors has initiated a search for the Company's next Chief Executive Officer and that Blaise Coleman will depart the Company as President & CEO and from the Board of Directors, effective on August 29, 2024 . The Board has retained Spencer Stuart , a leading executive search firm, to assist in the search process. Scott Hirsch has been appointed to serve as Endo's Interim CEO in the transition period while the search is ongoing.
Mr. Hirsch joined the Endo Board of Directors in April 2024 . He has over 20 years of experience in healthcare, investment management, and financial services and was formerly the CEO of Solta Medical, where he led growth of the global business through an expansion cycle.
Prior to Solta, Mr. Hirsch was the President of the Ortho Dermatologics and OraPharma business segments and the Chief Business Officer of Bausch Health/Bausch & Lomb. Paul Herendeen , Chairman of the Board of Directors, said, "Following the completion of our reorganization, Endo is strategically well-positioned to become a vibrant growth company with a strong balance sheet, a broad, diversified portfolio of on-market medicines, and a pipeline of innovative and differentiated product candid.